Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

181. Interactions between warfarin and three commonly prescribed fluoroquinolones Full Text available with Trip Pro

Interactions between warfarin and three commonly prescribed fluoroquinolones Interactions between warfarin and three commonly prescribed fluoroquinolones Interactions between warfarin and three commonly prescribed fluoroquinolones Carroll D N, Carroll D G CRD summary This review evaluated a potential increased anticoagulant response during concomitant therapy of warfarin and three commonly prescribed fluoroquinolones. Due to inconsistent findings, the authors concluded (...) that there was insufficient evidence to support a potential increased anticoagulant response. The authors' conclusions were appropriate, but should be considered in the context of the review's methodological weaknesses. Authors' objectives To critically assess a potential increased anticoagulant response during concomitant therapy of warfarin and any of the three commonly prescribed fluoroquinolone antibiotics. Searching MEDLINE/PubMed and International Pharmaceutical Abstracts were searched from inception to January

2008 DARE.

182. The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin

The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin Article Text Clinical prediction guide The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin

2007 Evidence-Based Medicine

183. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?

What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? BestBets: What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Report By: Andrew Bayliss, Peter Faber, Joel (...) with [mechanical prosthetic mitral valve] receiving long-term [warfarin therapy] what is the [optimal therapeutic INR target]? Clinical Scenario You have inserted a mechanical prosthetic mitral heart valve into a 60-year-old man. He subsequently has a GI bleed while on warfarin so you decide to review the literature to confirm optimal therapeutic INR which minimises long-term thromboembolic and haemorrhagic complications. Search Strategy Medline 1966 to 2006 November Week 3 using OVID interface. EMBASE 1980

2007 BestBETS

184. Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes

Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes

2007 Evidence-Based Medicine

185. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. (Abstract)

Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Preoperative low-molecular-weight heparin (LMWH) is often used when warfarin therapy is interrupted for surgery.To determine the preoperative anticoagulant activity of LMWH following a standardized "bridging" regimen.Prospective cohort study.Single university hospital.Consecutive patients who had warfarin therapy interrupted before an invasive

2007 Annals of Internal Medicine

186. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. (Abstract)

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown. We assessed whether warfarin reduced risk of major stroke, arterial (...) embolism, or other intracranial haemorrhage compared with aspirin in elderly patients.973 patients aged 75 years or over (mean age 81.5 years, SD 4.2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day). Follow-up was for a mean of 2.7 years (SD 1.2). The primary endpoint was fatal or disabling stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or clinically significant arterial

2007 Lancet Controlled trial quality: predicted high

187. Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care Full Text available with Trip Pro

Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. Article Text Therapeutics Warfarin reduced major stroke more than

2007 Evidence-Based Medicine

188. Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement?

Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement? BestBets: Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement? Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement? Report By: Moataz El-Husseiny, Kareem Salhiyyah, Shahzad G. Raja - Cardiothoracic Registrars Search checked by Joel Dunning - Cardiothoracic Registrar RCS (...) for a bioprosthesis as her mother was on warfarin in the past and it had 'never agreed with her'. She is then quite disappointed when you tell her that she will actually have to be on warfarin for 3-months after the operation, and asks what would happen if she didn't take it. You can't quote her a figure of increased risk and therefore resolve to look up the answer. Search Strategy Medline 1966–May 2006 [exp Warfarin/ OR exp Anticoagulants/ OR anticoagulation.mp. OR antithrombo$.mp OR warfarin.mp OR vitaminK

2007 BestBETS

189. Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Full Text available with Trip Pro

Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Article Text Therapeutics Warfarin

2006 Evidence-Based Medicine

190. Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Full Text available with Trip Pro

Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Article Text

2006 Evidence-Based Medicine

191. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. Full Text available with Trip Pro

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. To quantify the influence of physicians' experiences of adverse events in patients with atrial fibrillation who were taking warfarin.Population based, matched pair before and after analysis.Database study in Ontario, Canada.The physicians of patients with atrial fibrillation admitted to hospital for adverse events (major haemorrhage while taking warfarin and thromboembolic strokes while (...) not taking warfarin). Pairs of other patients with atrial fibrillation treated by the same physicians were selected.Odds of receiving warfarin by matched pairs of a given physician's patients (one treated after and one treated before the event) were compared, with adjustment for stroke and bleeding risk factors that might also influence warfarin use. The odds of prescriptions for angiotensin converting enzyme (ACE) inhibitor before and after the event was assessed as a neutral control.For the 530

2006 BMJ

192. Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials

Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials Yoshida W B, El Dib R P, de Alvarenga Yoshida R (...) , de Abreu Maffei F H CRD summary This review evaluated ximelagatran as prophylactic treatment in older patients undergoing knee surgery. The authors concluded that a higher dose of ximelagatran is more effective than warfarin in reducing the incidence of venous thromboembolism, but it increases the frequency of alanine aminotranferase elevation in the follow-up period. This was a well-conducted review and the conclusions are likely to be reliable. Ximelagatran has since been withdrawn from

2006 DARE.

193. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

194. Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement Full Text available with Trip Pro

infarction, or receipt of study drug ⩽30 days before surgery; increased risk of bleeding ⩽90 days before surgery; increased risk of bleeding ⩽90 days before surgery; uncontrolled hypertension; thrombocytopenia; drug or alcohol abuse in the past 6 months; and potential for pregnancy. Intervention: twice-daily tablets of ximelagatran (Exanta, AstraZeneca), 36 mg (n = 775); 24 mg (n = 762); or once daily warfarin (Coumadin, Bristol-Myers Squibb) (n = 764). Placebos were given for each study drug (...) Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers

2005 Evidence-Based Medicine

195. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. Full Text available with Trip Pro

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin.We conducted a retrospective study of European-American patients receiving long-term warfarin maintenance therapy. Multiple linear-regression analysis was used to determine the effect of VKORC1 haplotypes (...) on the warfarin dose. We determined VKORC1 haplotype frequencies in African-American, European-American, and Asian-American populations and VKORC1 messenger RNA (mRNA) expression in human liver samples.We identified 10 common noncoding VKORC1 single-nucleotide polymorphisms and inferred five major haplotypes. We identified a low-dose haplotype group (A) and a high-dose haplotype group (B). The mean (+/-SE) maintenance dose of warfarin differed significantly among the three haplotype group combinations, at 2.7

2005 NEJM

196. Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Full Text available with Trip Pro

Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Article Text Therapeutics Ximelagatran was non-inferior to warfarin

2005 Evidence-Based Medicine

197. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. Full Text available with Trip Pro

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple therapeutic alternative to current standard treatment of acute venous thromboembolism.To compare the efficacy and safety of ximelagatran with standard enoxaparin/warfarin treatment for the prevention of recurrent venous (...) followed by warfarin adjusted to maintain an international normalized ratio of 2.0 to 3.0.Recurrent venous thromboembolism, bleeding, and mortality.Venous thromboembolism recurred in 26 of the 1240 patients assigned to receive ximelagatran (estimated cumulative risk, 2.1%) and in 24 of the 1249 patients assigned to receive enoxaparin/warfarin (2.0%). The absolute difference between ximelagatran and enoxaparin/warfarin was 0.2% (95% confidence interval [CI], -1.0% to 1.3%). This met the prespecified

2005 JAMA Controlled trial quality: predicted high

198. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. Full Text available with Trip Pro

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. In patients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use.To compare the efficacy of the oral direct thrombin inhibitor ximelagatran with warfarin for prevention of stroke and systemic embolism.Double-blind, randomized, multicenter trial (2000-2001) conducted at 409 North American (...) sites, involving 3922 patients with nonvalvular atrial fibrillation and additional stroke risk factors.Adjusted-dose warfarin (aiming for an international normalized ratio [INR] 2.0 to 3.0) or fixed-dose oral ximelagatran, 36 mg twice daily.The primary end point was all strokes (ischemic or hemorrhagic) and systemic embolic events. The primary analysis was based on demonstrating noninferiority within an absolute margin of 2.0% per year according to the intention-to-treat model.During 6405 patient

2005 JAMA Controlled trial quality: predicted high

199. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. Full Text available with Trip Pro

Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial.We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target (...) international normalized ratio, 2.0 to 3.0) or aspirin (1300 mg per day) in a double-blind, multicenter clinical trial. The primary end point was ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke.After 569 patients had undergone randomization, enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive warfarin. During a mean follow-up period of 1.8 years, adverse events in the two groups included death (4.3 percent

2005 NEJM Controlled trial quality: predicted high

200. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Full Text available with Trip Pro

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care (...) with chronic non-valvular atrial fibrillation who were receiving warfarin. The eligibility criteria for the patients were: 18 years of age or older; treated with warfarin at an anticoagulation clinic for at least 30 days; evidence of atrial fibrillation in the medical chart, but no evidence of mitral stenosis, severe mitral insufficiency, or severe tricuspid regurgitation noted in echocardiography reports; and no participation in prospective clinical studies involving anticoagulation care during the study

2005 NHS Economic Evaluation Database.